Holen Sie sich die Stockscreener-App
4.45
10.70%
0.43
Handel nachbörslich:
4.53
0.08
+1.80%
Schlusskurs vom Vortag:
$4.02
Offen:
$4.01
24-Stunden-Volumen:
144.59K
Relative Volume:
1.20
Marktkapitalisierung:
$38.45M
Einnahmen:
$140.46M
Nettoeinkommen (Verlust:
$-146.34M
KGV:
-3.5039
EPS:
-1.27
Netto-Cashflow:
$-117.73M
1W Leistung:
+10.42%
1M Leistung:
-2.20%
6M Leistung:
-51.34%
1J Leistung:
-64.36%
1-Tages-Spanne:
$4.01
$4.60
1-Wochen-Bereich:
$3.6503
$4.60
52-Wochen-Spanne:
$3.51
$16.95
Karyopharm Therapeutics Inc Stock (KPTI) Company Profile
Firmenname
Karyopharm Therapeutics Inc
Sektor
Branche
Telefon
617-658-0600
Adresse
85 WELLS AVENUE, NEWTON, MA
Vergleichen Sie KPTI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KPTI
Karyopharm Therapeutics Inc
|
4.45 | 32.57M | 140.46M | -146.34M | -117.73M | -1.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-16 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-07-11 | Fortgesetzt | H.C. Wainwright | Buy |
| 2023-01-19 | Eingeleitet | Piper Sandler | Overweight |
| 2022-11-04 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-09 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-11-19 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2021-08-06 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-08-06 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-08-06 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-07-02 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-17 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-07-23 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-07-05 | Bestätigt | H.C. Wainwright | Buy |
| 2019-07-05 | Bestätigt | Robert W. Baird | Outperform |
| 2019-03-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-02-28 | Bestätigt | BofA/Merrill | Underperform |
| 2019-02-27 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2019-01-03 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2018-12-03 | Eingeleitet | B. Riley FBR | Buy |
| 2018-11-09 | Hochstufung | Wedbush | Neutral → Outperform |
| 2018-05-24 | Herabstufung | Wedbush | Outperform → Neutral |
| 2018-04-02 | Fortgesetzt | Leerink Partners | Outperform |
| 2017-11-15 | Fortgesetzt | H.C. Wainwright | Buy |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2016-09-08 | Bestätigt | H.C. Wainwright | Buy |
| 2016-08-30 | Hochstufung | Jefferies | Hold → Buy |
| 2016-08-18 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-06-28 | Eingeleitet | Robert W. Baird | Outperform |
Alle ansehen
Karyopharm Therapeutics Inc Aktie (KPTI) Neueste Nachrichten
Karyopharm Therapeutics’ SWOT analysis: biotech firm’s stock faces pivotal year - Investing.com
Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Lags Revenue Estimates - MSN
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q2 2025 Earnings Call Transcript - Insider Monkey
Karyopharm’s Earnings Call: Clinical Wins Amid Financial Strain - TipRanks
Karyopharm Therapeutics: Q2 Earnings Snapshot - Connecticut Post
Karyopharm Therapeutics Inc (KPTI) Q2 2025 Earnings Call Highlights: Navigating Financial ... - ca.finance.yahoo.com
Karyopharm Therapeutics Reports Q2 2025 Earnings - TipRanks
Karyopharm’s Revenue Dips As Drug Sales Inch Upward - Finimize
Karyopharm Sees Mixed Q2 As XPOVIO Sales Climb - Finimize
Karyopharm outlines $1B peak U.S. revenue opportunity in myelofibrosis with pivotal Phase III data expected by March 2026 - MSN
Karyopharm Reports Q2 2025 Financial Results, Updates Guidance, and Explores Financing and Strategic Alternatives - AInvest
Karyopharm Therapeutics Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:KPTI) - Seeking Alpha
Earnings call transcript: Karyopharm Q2 2025 sees revenue decline amid strategic shifts - Investing.com
Karyopharm Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Transcript : Karyopharm Therapeutics Inc., Q2 2025 Earnings Call, Aug 11, 2025 - MarketScreener
Karyopharm Reports Second Quarter 2025 Financial Results and Highlights Recent Company Progress - Citizen Tribune
Karyopharm Q2 2025 slides: Myelofibrosis pivot amid mixed financial results By Investing.com - Investing.com South Africa
Karyopharm Therapeutics Q2 revenue falls 11% - MarketScreener
Karyopharm Therapeutics Inc. SEC 10-Q Report - TradingView
Karyopharm Q2 rev. $37.9mln, up 6% YoY; updates FY guidance. - AInvest
Multi Factor Analysis Ranks Karyopharm Therapeutics Inc. as Strong BuyMomentum Based Equity Trading Plans Reviewed - beatles.ru
Layoff Tracker: Bicycle, Tune, Iovance, Precision Downsize to Conserve Cash - BioSpace
Earnings Outlook For Karyopharm Therapeutics - 富途牛牛
Visual trend scoring systems applied to Karyopharm Therapeutics Inc.Technical Reversal Setup with Risk Limits - Newser
Automated trading signals detected on Karyopharm Therapeutics Inc.Free Community Strategy With High Win Rate - Newser
Chart based exit strategy for Karyopharm Therapeutics Inc.Secure Entry Point Finder with Analysis - Newser
How moving averages guide Karyopharm Therapeutics Inc. tradingMarket Timing Strategy with Technical Filters - Newser
Karyopharm Therapeutics shares rise 1.78% after-hours following Bicycle Therapeutics' board expansion. - AInvest
Karyopharm Therapeutics Inc expected to post a loss of $4.10 a shareEarnings Preview - TradingView
Tick level data insight on Karyopharm Therapeutics Inc. volatilityTechnical Trade Plan with Entry Checklist - Newser
How Karyopharm Therapeutics Inc. stock reacts to Fed policy changesFree Weekly Potential Breakout Stock List - Newser
Karyopharm Therapeutics Inc (KPTI) Q2 2025 Earnings Report Preview: What To Expect - Yahoo Finance
What data driven models say about Karyopharm Therapeutics Inc.’s futureBuy Strategy Review With Performance Summary - Newser
Karyopharm to Report Second Quarter 2025 Financial Results on August 11, 2025 - Eastern Progress
Karyopharm Therapeutics Inc. stock prediction for this weekAI Swing Strategy Signal Forecasting System - Newser
Candlestick signals on Karyopharm Therapeutics Inc. stock todayHigh Reward Picks with Tight Risk Control - Newser
Is a relief rally coming for Karyopharm Therapeutics Inc. holdersFast Entry Strategy with Price Prediction - Newser
Karyopharm to Report Second Quarter 2025 Financial Results on Au - GuruFocus
Will Karyopharm Therapeutics Inc. stock split in the near futureStock Price Prediction Using AI Tools - Newser
Karyopharm Therapeutics Inc. Sees Spike in Bullish Option FlowPattern Alert With ROI Driven Strategy Shared - beatles.ru
Is Karyopharm Therapeutics Inc. a growth stock or a value stockTriple-digit profit margins - Jammu Links News
Why is Karyopharm Therapeutics Inc. stock attracting strong analyst attentionUnlock real-time trading signals for gains - Jammu Links News
What makes Karyopharm Therapeutics Inc. stock price move sharplyUnlock powerful portfolio management tools - Jammu Links News
How does Karyopharm Therapeutics Inc. compare to its industry peersAchieve impressive returns with smart timing - Jammu Links News
What is the risk reward ratio of investing in Karyopharm Therapeutics Inc. stockBuild a winning portfolio with smart picks - Jammu Links News
Will Karyopharm Therapeutics Inc. see short term momentumFree AI Screening for Swing Trade Picks - Newser
What institutional investors are buying Karyopharm Therapeutics Inc. stockFree Daily Trading Room Entry - Jammu Links News
Should I hold or sell Karyopharm Therapeutics Inc. stock in 2025Overwhelming financial success - Jammu Links News
When is Karyopharm Therapeutics Inc. stock expected to show significant growthCapitalize on fast-moving stock opportunities - Jammu Links News
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Eastern Progress
Is Karyopharm Therapeutics Inc. stock overvalued or undervaluedRapid portfolio appreciation - Jammu Links News
Finanzdaten der Karyopharm Therapeutics Inc-Aktie (KPTI)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):